Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
Authors
Keywords
AML, Therapy, Targeted therapy, Prognosis, Biology
Journal
Clinical Lymphoma Myeloma & Leukemia
Volume 21, Issue 9, Pages 580-597
Publisher
Elsevier BV
Online
2021-05-30
DOI
10.1016/j.clml.2021.05.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acute myeloid leukemia: current progress and future directions
- (2021) Hagop Kantarjian et al. Blood Cancer Journal
- Mayo Clinic experience with 1123 adults with acute myeloid leukemia
- (2021) Kebede H. Begna et al. Blood Cancer Journal
- De novo acute myeloid leukemia: A population‐ based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
- (2021) Koji Sasaki et al. CANCER
- Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape
- (2021) Nicholas J. Short et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
- (2021) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
- (2020) Thomas Cluzeau et al. BLOOD
- Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
- (2020) David A Sallman et al. BLOOD
- Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)
- (2020) Gautam M. Borthakur et al. BLOOD
- Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study
- (2020) Courtney D. DiNardo et al. BLOOD
- Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)
- (2020) Melhem M Solh et al. LEUKEMIA RESEARCH
- Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML
- (2020) Guillermo Garcia-Manero et al. BLOOD
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
- (2020) Chong Chyn Chua et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
- (2020) Jeffrey E. Lancet et al. Blood Advances
- Acute myeloid leukemia: 2021 update on risk‐stratification and management
- (2020) Elihu H. Estey AMERICAN JOURNAL OF HEMATOLOGY
- Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
- (2020) Eytan M. Stein et al. BLOOD
- Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A
- (2020) Marius Bill et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia
- (2020) Nicholas J. Short et al. JAMA Oncology
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
- (2020) Paola Minetto et al. Cancers
- Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
- (2019) Gerwin Huls et al. BLOOD
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline Chest Computed Tomography for Early Diagnosis of Invasive Pulmonary Aspergillosis in Hemato-oncological Patients- a Prospective Cohort Study
- (2019) Roni Bitterman et al. CLINICAL INFECTIOUS DISEASES
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
- (2019) Naveen Pemmaraju et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia
- (2019) Kamal Chamoun et al. CANCER
- Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
- (2019) Gunnar Juliusson et al. BLOOD
- Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders
- (2019) Farhad Ravandi et al. HAEMATOLOGICA
- FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
- (2019) Weerapat Owattanapanich et al. Journal of Clinical Medicine
- Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study
- (2019) Mauricette Michallet et al. BLOOD
- Impact of the variant allele frequency of ASXL1 , DNMT3A , JAK2 , TET2 , TP53 , and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia
- (2019) Koji Sasaki et al. CANCER
- Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
- (2019) Linus Angenendt et al. JOURNAL OF CLINICAL ONCOLOGY
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
- (2019) Elise Fournier et al. BLOOD
- Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor
- (2019) Åsa Derolf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
- (2019) Szymon Klossowski et al. JOURNAL OF CLINICAL INVESTIGATION
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
- (2019) Christopher S. Hourigan et al. JOURNAL OF CLINICAL ONCOLOGY
- Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial
- (2018) Anna Candoni et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2b study of two dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML
- (2018) Jorge E. Cortes et al. BLOOD
- Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California
- (2018) Gwendolyn Ho et al. CANCER
- Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
- (2018) Farhad Ravandi et al. HAEMATOLOGICA
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial
- (2018) Hong-Hu Zhu et al. LANCET ONCOLOGY
- Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
- (2018) Peter Paschka et al. LEUKEMIA
- Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
- (2018) Prajwal Boddu et al. LEUKEMIA & LYMPHOMA
- Comparison of anthracyclines used for induction chemotherapy in patients with FLT3 -ITD-mutated acute myeloid leukemia
- (2018) Eun-Ji Choi et al. LEUKEMIA RESEARCH
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
- (2018) Farhad Ravandi et al. HAEMATOLOGICA
- Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial
- (2018) Nigel Russell et al. BLOOD
- Acute myeloid leukaemia
- (2018) Nicholas J Short et al. LANCET
- Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
- (2018) Tapan M Kadia et al. Lancet Haematology
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
- (2017) Uwe Platzbecker et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Precision oncology for acute myeloid leukemia using a knowledge bank approach
- (2017) Moritz Gerstung et al. NATURE GENETICS
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved outcome for AML patients over the years 2000–2014
- (2017) Sarah Bertoli et al. Blood Cancer Journal
- Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
- (2017) Mohamed L. Sorror et al. JAMA Oncology
- Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
- (2016) Anthony D. Ho et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab
- (2016) Yasmin Abaza et al. BLOOD
- Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
- (2016) Farhad Ravandi et al. CANCER
- TP53mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
- (2016) Tapan M. Kadia et al. CANCER
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
- (2016) Koichi Takahashi et al. Clinical Lymphoma Myeloma & Leukemia
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
- (2015) Bruno C. Medeiros et al. ANNALS OF HEMATOLOGY
- Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients
- (2015) M. Libura et al. BLOOD
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia
- (2015) Anna B. Halpern et al. BLOOD
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
- (2015) Tapan M. Kadia et al. CANCER
- Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies
- (2015) Hagop Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia
- (2015) Friederike Pastore et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation
- (2015) Christian Pfrepper et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
- (2015) Alan K Burnett et al. LANCET ONCOLOGY
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Toward Individualized Therapy in Acute Myeloid Leukemia
- (2015) Tapan M. Kadia et al. JAMA Oncology
- Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia
- (2014) Gautam Borthakur et al. AMERICAN JOURNAL OF HEMATOLOGY
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
- (2014) D. Grimwade et al. BLOOD
- Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia
- (2014) Friederike Pastore et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
- (2013) M. Pratcorona et al. BLOOD
- Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
- (2013) B. Lowenberg BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
- (2013) H.-H. Zhu et al. BLOOD
- Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
- (2013) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
- (2013) Roelof Willemze et al. JOURNAL OF CLINICAL ONCOLOGY
- Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
- (2013) M Othus et al. LEUKEMIA
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
- (2012) A. Quintas-Cardama et al. BLOOD
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
- (2012) J. A. L. Yin et al. BLOOD
- Survival for older patients with acute myeloid leukemia: a population-based study
- (2012) B. Oran et al. HAEMATOLOGICA
- Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
- (2012) Jerzy Holowiecki et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- RUNX1Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures
- (2012) Jason H. Mendler et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
- (2012) Stefan Gröschel et al. JOURNAL OF CLINICAL ONCOLOGY
- Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older
- (2012) Claude Gardin et al. JOURNAL OF CLINICAL ONCOLOGY
- AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
- (2011) G. Avvisati et al. BLOOD
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
- (2011) Felicitas Thol et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
- (2011) Jan Krönke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia
- (2011) Ardeshir Ghavamzadeh et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytarabine Dose of 36 g/m2Compared With 12 g/m2Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study
- (2011) Markus Schaich et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytarabine Dose for Acute Myeloid Leukemia
- (2011) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study
- (2010) S. Miyawaki et al. BLOOD
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
- (2010) H. Kantarjian et al. BLOOD
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
- (2010) B. L. Powell et al. BLOOD
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
- (2010) D. Grimwade et al. BLOOD
- Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
- (2010) Cecile Pautas et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
- (2010) Vikram Mathews et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12
- (2010) Christine J. Harrison et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
- (2009) S. Schnittger et al. BLOOD
- Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
- (2009) F. Giles et al. BLOOD
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10
- (2009) Franco Mandelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
- (2009) David Grimwade et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia
- (2009) H Seifert et al. LEUKEMIA
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
- Relapse and death during first remission in acute myeloid leukemia
- (2008) M. Yanada et al. HAEMATOLOGICA
- Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
- (2008) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically useful prognostic factors in acute myeloid leukemia
- (2007) Felicetto Ferrara et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started